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Workers at risk of exposure to uranium compounds should be monitored and their internal exposure quantified in terms 
of committed effective dose E(50) in mSv. In vitro bioassay methods can quantify uranium in urine and faeces at low 
activity levels. Alpha spectrometry (AS) is the most common method used for monitoring alpha-emitting radionuclides 
in internal dosimetry services. It provides isotopic information and low minimum detectable activity (MDA) values 
(≤0.50 mBq per sample). This study reports the results of a five-year monitoring of workers exposed to uranium at a 
Spanish Juzbado facility, which produces nuclear fuel elements enriched with up to 5 % of 235U. Monitoring included 
about 100 workers per year, most of whom had worked at the facility for more than 10 years before the individual 
monitoring programme was established. We analysed nearly 550 samples of more than 200 workers over five years. The 
obtained results indicate that workers were adequately protected from uranium exposure through inhalation and had an 
acceptably low chronic intake at the facility.
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The Juzbado facility of ENUSA Industrias Avanzadas 
S.A. (ENUSA) located in Salamanca (Spain) manufactures 
nuclear fuel elements for Spanish nuclear power plants. Its 
annual production capacity is 500 t of up to 5 % 235U-enriched 
uranium (1). The manufacturing process puts more than 
200 workers at risk of internal exposure, which is why they 
need to be monitored for internal exposure. Since 2014, 
CIEMAT has been assessing internal dosimetry of 
permanent staff of the facility (around 100 workers per 
year) in terms of committed effective dose E(50) in mSv. 
As in vivo methods are not always adequate for quantifying 
exposure to alpha emitters because their detection limits 
are too high (2), in vitro bioassay methods are preferred, as 
they quantify uranium in urine at low activity levels (3, 4). 
This is particularly relevant for radionuclides incorporated 
into the body as insoluble compounds through inhalation, 
because in this case the urinary excretion of uranium 
isotopes is low and slow (5).
The CIEMAT Bioelimination Laboratory uses three 
indirect methods of quantifying uranium: kinetic 
phosphorescence analysis (KPA), inductively coupled 
plasma-sector field mass spectrometry (ICP-SF-MS), and 
alpha spectrometry (AS). KPA or ICP-MS are employed 
for screening workers at risk of internal contamination by 
natural uranium. If the results obtained with these methods 
are above detection limit (0.10 µg/L for KPA and 
0.004 mBq/L (238U) for ICP-MS), an isotopic analysis with 
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AS is the next step. It is the reference and most common 
method used for monitoring alpha-emitting radionuclides 
in internal dosimetry services, as it provides isotope 
information and has a low minimum detectable activity 
(MDA) ≤0.50 mBq per sample. However, it takes tedious 
chemical processing to isolate actinides from inactive 
substances and separate them from other radioisotopes 
which may interfere with AS measurement. It also takes 
long counting times (3–5 days) (3–7).
The aim of this study was to establish potential internal 
exposure of workers at the Juzbado facility to enriched 
uranium compounds by monitoring about 100 workers per 
year over five years (2014–2018). Most of these workers 
had been working at the facility for more than 10 years 
before the individual monitoring program was established. 
We applied a new method developed for the separation and 
analysis of uranium isotopes (238U, 236U, 235U, and 234U) in 
urine samples using ion exchange chromatography and 
alpha spectrometry. It is an adaptation of an older procedure 
used at our laboratory (8), and its main novelty is that it can 
be applied for chronic inhalation scenarios. Earlier 
measurement methods (such as in vivo whole body counter 
and kinetic phosphorescence analysis in urine) were less 
sensitive and used only for accidental exposures or when 
activity was above the detection limit, in which case they 
were followed up by AS to confirm contamination. Since 
2014, CIEMAT has established an improved radiochemical 
procedure for individual monitoring of Spanish workers 
exposed to enriched uranium for 10–30 years as part of 
routine internal exposure monitoring programme (9). The 
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accuracy and reliability of this analytical procedure have 
been tested and validated at international intercomparison 
exercises. CIEMAT Bioelimination Laboratory also has the 
ISO/IEC 17025 accreditation since 2012 (10, 11).
This report presents the activity results (mBq/day) of a 
five-year monitoring of urine samples taken from the 
Juzbado workers, which reflect their chronic intake (internal 
doses) through inhalation. 
METHODS AND VALIDATION
Chronically inhaled internal doses are assessed 
following the International Commission on Radiological 
Protection (ICRP) recommendations and biokinetic models 
(12, 13). Routine monitoring of workers exposed to enriched 
uranium (3–5 %) assumed only inhalation intake and 
chronic exposure. The intake scenario assumed exposure 
to uranium oxides with type S of solubility and a default 
particle size of 5 µm of activity median aerodynamic 
diameter (AMAD) (9). For that purpose 24-hour urine 
samples were required, initially at annual frequency. New 
employees gave a urine sample before exposure began for 
background subtraction.
Samples were collected and creatinine content was 
determined according to the method described by Young 
(14), based on the formation of a coloured complex with a 
basic picrate solution. Sample volume was corrected 
assuming an average creatinine excretion rate of 1.7 g/day 
for men and 1.0 g/day for women (15) to normalise 
radionuclide amount measured in the sample to the 
equivalent of a true 24-hour collection.
Analytical procedures
All chemicals used were of analytical grade quality and 
solutions were prepared with deionised water. Anion 
exchange resin AG1-X8 (100–200 dry mesh, chloride form) 
was purchased from Bio-Rad Laboratories (Irvine, CA, 
USA). Radionuclide reference solution used as tracer (232U) 
was metrologically traceable to the Ionizing Radiation 
Metrology Laboratory (LMRI) of CIEMAT.
Figure 1 shows a flow chart of the analytical procedure 
used to determine uranium isotopes in urine, which consists 
of three main preparation steps (pre-concentration step, 
radiochemical separation, and electrodeposition) prior to 
AS.
Pre-concentration step
The whole sample was transferred into a glass beaker, 
acidified with concentrated HNO3 (65 %), and 1 mL of 
concentrated phosphoric acid (85 %) was added to initiate 
the process. Isotopic tracer (232U) was added to quantify 
recovery of the analytical procedure. Sample and tracer 
were equilibrated by heating and magnetic stirring in a water 
bath at 80 °C for at least 30 min. Uranium isotopes were 
then co-precipitated with calcium phosphate in ammonia 
with continuous stirring for 1 h. The precipitate was left to 
settle overnight and was then separated by decanting and 
centrifugation. The supernatant was discarded and the 
precipitate centrifuged, washed with 2 mol/L of HNO3 and 
finally evaporated to dryness. The residue was then wet 
ashed up to five times with 3–5 mL of concentrated HNO3 
at 300 °C. Finally, the obtained residue was dissolved in 
50 mL of HCl (10 mol/L).
Radiochemical separation
Uranium was  i so la ted  by  an ion  exchange 
chromatography using AG1-X8 resin. About 8–10 g of resin 
(suspended in H2O) was transferred into a glass column and 
rinsed with 2x30 mL of 10 mol/L HCl. The sample solution 
was then loaded in the column, and the resin washed with 
4x25 mL of 10 mol/L HCl. Uranium isotopes were then 
eluted with 4x20 mL of 0.5 mol/L HCl.
Electrodeposition
The uranium fraction was evaporated to dryness and 
prepared for alpha particle counting by electrodeposition 
following the procedure described by Hallstadius (16).
Alpha spectrometry
Alpha spectra were measured with an integrated 
Canberra Alpha Analyst instrument (Model 7200) (Meriden, 
CT, USA) equipped with passivated implanted planar 
Figure 1 Flow chart of the analytical procedure for the 
measurement of uranium isotopes in 24-hour urine samples
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silicon detectors with a 450 mm2 active area and full width 
at half-maximum (FWHM) alpha resolution of 18 KeV at 
5.48 MeV.
Figure 2 shows a typical spectrum with enriched 
uranium isotopes (the 232U peak is due to the tracer added). 
The typical energy resolution of a monoenergetic (or nearly 
monoenergetic) peak in the alpha spectrum in urine samples 
ranged between 20 to 30 KeV.
Internal dose assessment
The committed effective dose E(50) was calculated 
using Integrated Modules for Bioassay (IMBA) internal 
dosimetry software (17) and applying IDEAS Guidelines 
(General guidelines for the estimation of committed 
effective dose from incorporation monitoring data) (18) 
together with the methodology described in ISO 27048 (19) 
and ISO 16638-1 (5) standards for the estimation of 
uncertainty and the calculation of intake, including the 
verification of the “goodness of fit” to confirm that 
experimental data follow the prediction of the excretion 
model for the intake scenarios.
Quality assurance of the analytical method
The complete method was validated and uncertainty 
estimated according to accreditation requirements (20). 
Furthermore, the whole procedure and its results underwent 
quality assurance through participation in intercomparison 
exercises. Every year, the CIEMAT laboratory participates 
in different intercomparison exercises organised by the 
German Federal Office for Radiation Protection BfS 
(Bundesamt für Strahlenschutz) (21) and the French 
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association PROCORAD (Association pour la Promotion 
du Contrôle de Qualité des Analyses de Biologie Médicale 
en Radiotoxicologie) (22).
Table 1 shows the results validated by the BfS exercise 
“BfS-Rv-2015-U-nat” in 2015 and PROCORAD 
intercomparison exercise “Uranium in Urine Exercise” in 
2018. Bias and Z-score were within the confidence interval 
defined by ISO 28218 (23) [-25%, +50% and ≤2, 
respectively].
RESULTS AND DISCUSSION
From 2014 to 2018, nearly 550 urine samples (between 
77 and 133 a year) from more than 200 workers (about 100 
a year) were analysed with this radiochemical method. The 
obtained tracer recoveries in Table 2 show the reliability 
and robustness of the whole procedure. Thanks to these 
average recoveries, counting time of 300.000 s, counting 
efficiency of 26–31 %, and typical background range of 
0–4 counts, MDA was lowered to 0.05–0.19 mBq per 
sample. The need for lowering MDA is the consequence of 
extremely low daily urinary excretion rates for uranium 
radionuclides.
Activity results showed great variability, from values 
below MDA to activity rates of 18.89 mBq/day. However, 
most were below 5 mBq/day (Figure 3). The most 
significant average activity of 234U of around 2–3 mBq/day 
remained stable throughout the five years of monitoring. 
Only 5.6–17.7 % of the analysed samples had activity higher 
than 5 mBq/day. More precisely, it was stable at about 
7 mBq/day. For this reason, routine monitoring programme 
Figure 2 Typical alpha spectra for enriched uranium isotopes in a 24-hour urine sample
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frequency for the most exposed workers (receiving 5 mSv/
year or more) was doubled from annual to biannual.
Furthermore, these monitoring findings suggest that the 
workers at the Juzbado facility were effectively protected 
from uranium exposure through inhalation and had an 
acceptably low chronic intake.
Based on the 234U alpha spectrometry results with MDA 
of 0.5 mBq/day) and the isotopic composition of enriched 
uranium of around 4%, the committed effective dose E(50) 
for a worker who exposed to chronic inhalation for 10 years 
when the first 24-hour urine sample is collected was 
calculated to be around 0.3 mSv/year.
CONCLUSIONS
The analytical methodology developed by CIEMAT for 
in vitro bioassay of enriched uranium in urine is adequate 
to describe chronic inhalation exposure (routine monitoring) 
and accidental acute exposure. The obtained results 
prompted us to double the frequency of routine monitoring 
to biannual  for samples of the most exposed workers at the 
facility. However, for most of the workers the daily activity 
rate of uranium isotopes in urine samples over five years 
confirmed low level chronic intakes and verify a correct 
protection of workers.
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Table 1 Uranium isotope target values and activity concentrations measured in the 2015 Bfs sample and in the 2018 PROCORAD 
samples
BfS exercise (2015) mBq/L
Sample Nuclide Target value Measured value Bias (%) Z-score
A 234U 49.9±1.57 45.5±1.66 -9 0.442
A 235U 2.34±0.16 2.33±0.22 0 <0.10
A 238U 50.9±1.35 46.1±1.49 -10 0.478
PROCORAD exercise (2018) mBq/sample
Sample Nuclide Target value Measured value Bias (%) Z-score
A 234U 143.0± 11.3 140.0±14.0 -2 -0.2
235U 6.87±0.54 6.49±0.78 -6 -0.3
238U 142.0± 9.4 140.0±15.4 -1 -0.2
B 234U 37.1±3.74 34.0±4.42 -8 -0.8
235U 1.81±0.18 1.49±0.22 -18 -1.0
238U 36.7±3.34 34.2±4.44 -7 -0.9
Table 2 Uranium activity (234U) findings in the urine samples of the Juzbado workers
Year Average recovery (%) Total samples
Average activity (mBq/day)
Average activity >5 mBq/day
>MDA (0.50 mBq/sample)
2014 78 77 3.25±0.47 (n=76) 6.97±0.79 (n=14)
2015 69 98 2.56±0.48 (n=90) 7.86±0.98 (n=11)
2016 81 126 2.47±0.38 (n=110) 8.37±0.91 (n=15)
2017 83 133 2.02±0.34 (n=124) 7.41±0.86 (n=8)
2018 81 114 1.98±0.31 (n=105) 7.22±0.78 (n=7)
Figure 3 Distribution of 234U activity (mBq/day) in 2015
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Primjena bioeseja i alfa-spektrometrije za neizravno praćenje španjolskih radnika izloženih obogaćenom uraniju
Radnici koji su izloženi riziku od izloženosti spojevima s uranijem trebaju se pratiti i njihova unutrašnja izloženost mjeriti 
pomoću očekivane efektivne doze E(50) izražene u mSv. Uranij se može kvantificirati u mokraći čak i pri vrlo niskim 
razinama aktivnosti pomoću bioesejnih metoda in vitro. Najčešća metoda koja se rabi u internoj dozimetriji za praćenje/
nadziranje razina radionuklida koji emitiraju alfa-čestice jest alfa-spektrometrija. Njome se identificiraju izotopi i može 
otkriti nisku minimalnu aktivnost (engl. minimum detectable activity, MDA) (≤0.50 mBq po uzorku). Ovdje donosimo 
rezultate petogodišnjega praćenja radnika izloženih uraniju u španjolskoj tvornici sastojaka za nuklearno gorivo Juzbado, 
u kojoj se sastojci obogaćuju izotopom 235U do udjela od 5 %. Pratilo se oko 100 radnika na godinu, a većina njih je radila 
u tvornici više od deset godina prije nego što je uveden program praćenja. Ukupno je u pet godina analizirano gotovo 
550 uzoraka mokraće oko 200 radnika. Dobiveni rezultati upućuju na to da su radnici dobro zaštićeni od izloženosti 
uraniju udisanjem te da je kronični unos uranija u tvornici na prihvatljivo niskoj razini.
KLJUČNE RIJEČI: interna dozimetrija; izotopi uranija; neizravni bioesej; uzorci mokraće
